On October 21, 2026, the FDA granted accelerated approval to Ultomiris, a drug from Alexion, AstraZeneca's rare disease division, for adults with primary IgA nephropathy at risk of disease progression. A November 16, 2026 report from 24/7 Wall St. works through what this infusion drug could cost people on Medicare. The answer depends heavily on whether they have Original Medicare alone, a Medigap policy or a Medicare Advantage plan.
What the approval is based on
According to the report, the FDA relied on a predefined interim analysis of the I CAN Phase III trial, which enrolled 584 adults across 28 countries.
- Ultomiris cut proteinuria (protein in the urine) by 43.4% compared with placebo at 34 weeks.
- The urine protein-to-creatinine ratio fell 46.6% on the drug and 5.6% on placebo.
- The New England Journal of Medicine published the interim results.
Proteinuria is a surrogate marker. The report notes that the drug's label states researchers have not established whether Ultomiris slows the decline of kidney function. A second trial endpoint, kidney function measured at week 106, is meant to support traditional approval, and full approval may depend on that result.
The cost example under Original Medicare
The report uses a hypothetical 67-year-old with Original Medicare and no Medigap, retiree coverage or Medicaid. All figures use 2026 Part B rules.
- Ultomiris dosing depends on body weight. At 75 kilograms, his maintenance dose is 3,300 milligrams.
- At the October 2026 Part B payment benchmark, that dose carries about $74,730 in Medicare-allowed payment.
- After the $283 annual Part B deductible, he owes 20%, or $14,946.
- If the infusion is his first Part B claim of the year, his share is about $15,172.
Maintenance infusions come every eight weeks after an initial loading dose. The report estimates six maintenance infusions would produce roughly $89,676 in drug coinsurance alone, not counting the loading dose. Actual first-year costs depend on when treatment starts. Original Medicare has no out-of-pocket cap.
Why the real bill may differ
The $74,730 figure is an estimate based on Medicare's October 2026 payment limit, which CMS updates quarterly. It differs from the list price and from what an infusion site bills. The report names three factors:
- Administration costs: The infusion center or hospital outpatient department bills separately for the infusion service and any facility fee, and the patient owes 20% of those too.
- Coverage requirements: FDA approval doesn't guarantee payment on every claim. Treatment must meet Medicare coverage and medical-necessity requirements, and contractors may have extra documentation or billing rules for the new use.
- Reduced coinsurance: Each quarter, CMS publishes a list of Part B drugs whose coinsurance drops below 20% under inflation-rebate rules. The report suggests checking whether Ultomiris is on the current list.
How Medigap fits in
According to the report, Medigap Plan G covers the 20% Part B coinsurance after the deductible. Plan N also covers that coinsurance, though some office and emergency room visits can carry copays.
Timing matters. Once the six-month Medigap open enrollment window that starts with Part B has closed, insurers in most states can medically screen applicants, and the report says someone with advancing kidney disease is a likely denial. A few states, including New York, Connecticut, Massachusetts and Maine, give broader guaranteed-issue rights. Rules vary by state.
How Medicare Advantage fits in
The report says Medicare's open enrollment runs October 15 through December 7, 2026, with changes taking effect January 1, 2027. A Medicare Advantage plan's in-network out-of-pocket maximum would cap drug costs in 2027, provided the plan covers Ultomiris for the condition and treatment comes from in-network providers. The report doesn't give specific plan maximums.
The report points to tradeoffs:
- A plan can require prior authorization for Ultomiris.
- Returning to Original Medicare later would likely mean facing Medigap medical underwriting again.
Other points to raise with the care team
- Written estimate: The report suggests asking the infusion site to run a benefits verification for IgA nephropathy listing dose, billing code and site of care, with administration and facility fees included.
- Plan details: Anyone comparing Advantage plans can check on Medicare Plan Finder whether their nephrologist and infusion center are in network, along with each plan's prior authorization criteria and in-network maximum.
- Help with coinsurance: Medicare beneficiaries generally cannot use manufacturer copay cards, but independent charitable foundations may offer assistance if funding is available.
- Safety: Ultomiris carries a serious meningococcal infection warning. The report suggests asking the nephrologist about required vaccinations and the drug's safety program.
Not affiliated with Medicare or any government agency. Coverage and costs vary by plan and state.
Based on reporting by 24/7 Wall St., published November 16, 2026. Confirm details with Medicare.gov or your plan before you act.
